Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 2
2008 1
2013 1
2016 2
2017 4
2018 1
2019 1
2020 4
2021 4
2022 4
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Pros-IT CNR: an Italian prostate cancer monitoring project.
Noale M, Maggi S, Artibani W, Bassi PF, Bertoni F, Bracarda S, Conti GN, Corvò R, Gacci M, Graziotti P, Magrini SM, Maurizi Enrici R, Mirone V, Montironi R, Muto G, Pecoraro S, Porreca A, Ricardi U, Tubaro A, Zagonel V, Zattoni F, Crepaldi G; Pros-IT CNR study group. Noale M, et al. Aging Clin Exp Res. 2017 Apr;29(2):165-172. doi: 10.1007/s40520-017-0735-6. Epub 2017 Feb 24. Aging Clin Exp Res. 2017. PMID: 28236267
Extreme hypofractionated stereotactic radiotherapy for elderly prostate cancer patients: side effects preliminary analysis of a phase II trial.
Gregucci F, Carbonara R, Surgo A, Ciliberti MP, Curci D, Ciocia A, Branà L, Ludovico GM, Scarcia M, Portoghese F, Caliandro M, Ludovico E, Paulicelli E, Di Guglielmo FC, Bonaparte I, Fiorentino A. Gregucci F, et al. Among authors: ludovico gm. Radiol Med. 2023 Apr;128(4):501-508. doi: 10.1007/s11547-023-01618-5. Epub 2023 Mar 23. Radiol Med. 2023. PMID: 36952115 Clinical Trial.
Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study.
Procopio G, Chiuri VE, Giordano M, Alitto AR, Maisano R, Bordonaro R, Cinieri S, Rossetti S, De Placido S, Airoldi M, Galli L, Gasparro D, Ludovico GM, Guglielmini PF, Carella C, Nova P, Aglietta M, Schips L, Beccaglia P, Sciarra A, Livi L, Santini D; ABItude Study Group. Procopio G, et al. ESMO Open. 2022 Apr;7(2):100431. doi: 10.1016/j.esmoop.2022.100431. Epub 2022 Apr 8. ESMO Open. 2022. PMID: 35405438 Free PMC article.
Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette-Guerin Immunotherapy.
Ferro M, Tătaru OS, Musi G, Lucarelli G, Abu Farhan AR, Cantiello F, Damiano R, Hurle R, Contieri R, Busetto GM, Carrieri G, Cormio L, Del Giudice F, Sciarra A, Perdonà S, Borghesi M, Terrone C, La Civita E, Bove P, Autorino R, Muto M, Crisan N, Marchioni M, Schips L, Soria F, Terracciano D, Papalia R, Crocetto F, Barone B, Russo GI, Luzzago S, Ludovico GM, Vartolomei MD, Mistretta FA, Mirone V, de Cobelli O. Ferro M, et al. Among authors: ludovico gm. Diagnostics (Basel). 2022 Feb 25;12(3):586. doi: 10.3390/diagnostics12030586. Diagnostics (Basel). 2022. PMID: 35328139 Free PMC article.
26 results